This nanogel is engineered with Lys1Lys3-bombesin(1–14) modified with the chelator 1,4,7, 10-tetraazacyclododecane-1,4,7,10-tetraacetate (DOTA), enabling the precise transport of radionuclides such as Y-90 and Lu-117, which are applied in prostate cancer treatment [114]. The gene discussed is GRP; the disease is prostate carcinoma.